Medicines labeled for the same conditions

Alternatives to trastuzumab deruxtecan

14 other medicines are given the same way (intravenous) and in the same FDA class as trastuzumab deruxtecan or labeled mainly for the same use (breast cancer); the others include 4 her2/neu receptor antagonists, 3 microtubule inhibitors and 1 nucleoside metabolic inhibitor (FDA labels read October 8, 2026).

Which medicines are labeled for the same conditions as trastuzumab deruxtecan?

Breast cancer lists all 44 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.

Medicine and FDA class	Shared indication	Generic labelers (intravenous)	Pharmacy cost	Boxed warning	Shortage
Trastuzumab deruxtecan	this medicine	none listed	n/a	Yes	No current entry
Docetaxelmicrotubule inhibitor	Breast cancer, Lung cancer	14 labelers	n/a	Yes	A presentation being discontinued
Paclitaxelmicrotubule inhibitor	Breast cancer, Lung cancer	20 labelers	n/a	Yes	No current entry
Gemcitabinenucleoside metabolic inhibitor	Breast cancer, Lung cancer	10 labelers	n/a	No	No current entry
Eribulinmicrotubule inhibitor	Breast cancer	14 labelers	n/a	No	No current entry
Trastuzumabher2/neu receptor antagonist	Breast cancer	none listed	n/a	Yes	No current entry
Margetuximabher2/neu receptor antagonist	Breast cancer	none listed	n/a	Yes	No current entry
Trastuzumab emtansine	Breast cancer	none listed	n/a	Yes	No current entry
Trastuzumab-strfher2/neu receptor antagonist	Breast cancer	none listed	n/a	Yes	No current entry
Datopotamab deruxtecan	Breast cancer, Lung cancer	none listed	n/a	No	No current entry
Pembrolizumabprogrammed death receptor-1 blocking antibody	Breast cancer, Lung cancer	none listed	n/a	No	No current entry
Fulvestrantestrogen receptor antagonist	Breast cancer	1 labeler	n/a	No	A presentation being discontinued
Ixabepilone	Breast cancer	none listed	n/a	Yes	No current entry
Pertuzumabher2/neu receptor antagonist	Breast cancer	none listed	n/a	Yes	No current entry
Sacituzumab govitecan	Breast cancer	none listed	n/a	Yes	No current entry

Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)

What next?

Trastuzumab deruxtecan: the full record: label, generics, price, shortages, recalls